Brands should avoid implying that fiber ingredients help relieve GLP-1-associated constipation or other medication-related digestive effects unless that specific claim is directly substantiated
Tschop recounted his research with DiMarchi and that of others while he accepted the 2023 Banting Medal for Scientific Achievement at the 2023 American Diabetes Association Scientific Sessions.5 The FDA approved the first GLP-1 agonist, twice-a-day Byetta (exenatide), in 2005.1 Since then, several newer and more powerful medications in the GLP-1 agonist class, such as liraglutide and semaglutide, have received FDA approval for type 2 diabetes, with a higher dose of semaglutide FDA approved for weight loss.2 In mid-2022, the first dual agonist, tirzepetide (a combination of a GLP-1 agonist and a GIP), was FDA approved for type 2 diabetes
The copay also isnt eligible for the Medicare Prescription Payment Plan, which lets beneficiaries spread their out-of-pocket drug costs throughout the calendar year
Were leveraging our deep understanding of consumers and nutritional science to stay ahead of the trends that are shaping consumer behaviours and innovating across our portfolio to deliver products people will love. A multi-pronged approach There are several strands for manufacturers to think about when it comes to product development for GLP-1 users, believes Patel